Carregant...
Biosimilars in the management of neutropenia: focus on filgrastim
Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to...
Guardat en:
| Publicat a: | Biologics |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762467/ https://ncbi.nlm.nih.gov/pubmed/26937170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S73580 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|